Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

LL-37 regulatory status

Current status of LL-37 in the United States: Nomination withdrawn. In sport: WADA prohibited. Details, sources, and the dated timeline follow.

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

What is the current status of LL-37?

Regulatory: Nomination withdrawnWADA: WADA prohibitedVerified: Verified Sep 29, 2026
FDA and compounding
Not an FDA approved drug. FDA lists cathelicidin LL-37 among the bulk substances whose Category 2 nominations were withdrawn, so as of the last verification date it sits in no 503A category and is outside FDA's interim policy for Category 1 substances. FDA has said it will ask the Pharmacy Compounding Advisory Committee to consider LL-37 for the 503A bulks list at a meeting before the end of February 2027, but no date is set and no rule has been proposed. Because it is not on the bulks list and is not part of an approved drug, a 503A pharmacy has no federal basis to compound it from bulk. Not eligible for 503B outsourcing.
WADA
WADA prohibited
Access path
  1. Not available as an FDA approved product.
  2. It is off Category 2 but not on the 503A bulks list, so a 503A pharmacy has no federal basis to compound it from bulk.
  3. Products labeled research use only are unapproved drugs when sold for human use and are not verified for purity.

Full LL-37 page: evidence, dosing in the literature, and sources

How has the status of LL-37 changed over time?

  1. FDA

    FDA lists BPC-157 and 16 other peptides as withdrawn from 503A Category 2

    FDA's Category 2 page, current as of April 22, 2026, moved BPC-157, AOD-9604, CJC-1295, dihexa, DSIP, epitalon, injectable GHK-Cu, ipamorelin, KPV, LL-37, melanotan II, MOTS-c, PEG-MGF, selank, semax, thymosin alpha-1, and thymosin beta-4 fragment (TB-500) to a list of bulk drug substances nominated but withdrawn by their nominators. Withdrawal takes a substance off Category 2 but does not place it in Category 1, so FDA's interim compounding policy does not cover it, and it is not on the 503A bulks list. Ipamorelin acetate remains in 503B Category 2. Seven of the withdrawn peptides (BPC-157, KPV, TB-500, MOTS-c, semax, epitalon, and DSIP) were taken to the Pharmacy Compounding Advisory Committee in July 2026.

  2. FDA

    FDA places a batch of nominated peptides in 503A Category 2

    In September 2023 FDA updated its 503A bulk drug substances category lists to place a group of nominated peptides in Category 2, which means FDA identified significant safety risks and the substances may not be used in 503A compounding while the evaluation continues. Kisspeptin-10 and ibutamoren (MK-677) were added on September 29, 2023 and remain in Category 2 on the FDA page current as of April 22, 2026. BPC-157, CJC-1295, ipamorelin, AOD-9604, dihexa, DSIP, epitalon, KPV, MOTS-c, selank, semax, melanotan II, LL-37, thymosin alpha-1, and thymosin beta-4 fragment (TB-500) were also placed in Category 2 under the 503A interim policy; that same page now lists them as nominated but withdrawn (see the April 2026 event). Hexarelin, PNC-27, and 5-amino-1MQ have never appeared on the FDA category lists.

Sources

Numbered citations in the answers above point here, followed by the regulatory sources on record for LL-37 and the source of each dated event.

  1. [1]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA, 2026
  2. [2]FDA Pharmacy Compounding Advisory Committee meetings (July 2026 meeting on peptide nominations)FDA, 2026
  3. [3]WADA Prohibited List, section S0 non-approved substancesWADA, 2026
  4. [4]FDA warning letter 735063, August 24, 2026, to an online seller of research-use-only peptides: products labeled research use only were unapproved new drugs (FDA warning letters database)FDA, 2026
  5. [5]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (503A and 503B Category 2 lists and withdrawn nominations, content current as of April 22, 2026)FDA, 2026